Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 流行病學與預防醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76935
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor于明暉(Ming-Whei Yu)
dc.contributor.authorMeng-Hsuan Tsaien
dc.contributor.author蔡孟璇zh_TW
dc.date.accessioned2021-07-10T21:40:56Z-
dc.date.available2021-07-10T21:40:56Z-
dc.date.copyright2020-09-10
dc.date.issued2020
dc.date.submitted2020-08-07
dc.identifier.citation1. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1): 328-357.
2. Younossi ZM. Non-alcoholic fatty liver disease–A global public health perspective. Journal of hepatology. 2019;70(3): 531-544.
3. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2019;69(6): 2672-2682.
4. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1): 73-84.
5. Sharma S, Khalili K, Nguyen GC. Non-invasive diagnosis of advanced fibrosis and cirrhosis. World journal of gastroenterology: WJG. 2014;20(45): 16820.
6. Castera L. Noninvasive assessment of liver fibrosis. Digestive Diseases. 2015;33(4): 498-503.
7. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56(3): 943-951.
8. Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome. Circulation. 2005;112: 2735-2740.
9. Leite NC, Salles GF, Araujo AL, Villela‐Nogueira CA, Cardoso CR. Prevalence and associated factors of non‐alcoholic fatty liver disease in patients with type‐2 diabetes mellitus. Liver international. 2009;29(1): 113-119.
10. Marchesini G, Brizi M, Morselli-Labate AM, et al. Association of nonalcoholic fatty liver disease with insulin resistance. The American journal of medicine. 1999;107(5): 450-455.
11. Stefan N, Kantartzis K, Häring H-U. Causes and metabolic consequences of fatty liver. Endocrine reviews. 2008;29(7): 939-960.
12. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. The Lancet. 2013;382(9888): 260-272.
13. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. American Journal of Kidney Diseases. 2014;63(5): 713-735.
14. D NIoHNo, KD. 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. 2018.
15. Wheeler DC, Winkelmayer WC. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD) foreword. Kidney International Supplements. 2017;7(1): 1-59.
16. Isakova T, Nickolas TL, Denburg M, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD). American Journal of Kidney Diseases. 2017;70(6): 737-751.
17. Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international supplements. 2013;3(1): 1-150.
18. Blaufox M, Aurell M, Bubeck B, et al. Report of the Radionuclides in Nephrourology Committee on renal clearance. Journal of Nuclear Medicine. 1996;37(11): 1883-1888.
19. Fleming JS, Zivanovic MA, Blake GM, Burniston M, Cosgriff PS. Guidelines for the measurement of glomerular filtration rate using plasma sampling. Nuclear medicine communications. 2004;25(8): 759-769.
20. Levey AS, Coresh J, Bolton K, et al. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. American Journal of Kidney Diseases. 2002;39(2 SUPPL. 1).
21. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Annals of internal medicine. 1999;130(6): 461-470.
22. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Annals of internal medicine. 2009;150(9): 604-612.
23. Chen L-I, Guh J-Y, Wu K-D, et al. Modification of diet in renal disease (MDRD) study and CKD epidemiology collaboration (CKD-EPI) equations for Taiwanese adults. PloS one. 2014;9(6).
24. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2018;71(19): e127-e248.
25. Collins AJ, Vassalotti JA, Wang C, et al. Who should be targeted for CKD screening? Impact of diabetes, hypertension, and cardiovascular disease. American Journal of Kidney Diseases. 2009;53(3): S71-S77.
26. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). Jama. 2014;311(5): 507-520.
27. Group SR. A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine. 2015;373(22): 2103-2116.
28. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? Journal of hepatology. 2011;54(5): 1020-1029.
29. Targher G, Chonchol M, Bertolini L, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. Journal of the American Society of Nephrology. 2008;19(8): 1564-1570.
30. Chang Y, Ryu S, Sung E, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism. 2008;57(4): 569-576.
31. Sinn DH, Kang D, Jang HR, et al. Development of chronic kidney disease in patients with non-alcoholic fatty liver disease: a cohort study. Journal of hepatology. 2017;67(6): 1274-1280.
32. Targher G, Bertolini L, Rodella S, Lippi G, Zoppini G, Chonchol M. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clinical Journal of the American Society of Nephrology. 2010;5(12): 2166-2171.
33. Yeung M-W, Wong GL-H, Choi KC, et al. Advanced liver fibrosis but not steatosis is independently associated with albuminuria in Chinese patients with type 2 diabetes. Journal of hepatology. 2018;68(1): 147-156.
34. Wilechansky RM, Pedley A, Massaro JM, Hoffmann U, Benjamin EJ, Long MT. Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis. Liver International. 2019;39(8): 1535-1544.
35. Jang HR, Kang D, Sinn DH, et al. Nonalcoholic fatty liver disease accelerates kidney function decline in patients with chronic kidney disease: a cohort study. Scientific reports. 2018;8(1): 1-9.
36. Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS medicine. 2014;11(7).
37. Sirota JC, McFann K, Targher G, Chonchol M, Jalal DI. Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988–1994. American journal of nephrology. 2012;36(5): 466-471.
38. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. American journal of nephrology. 2004;24(2): 198-211.
39. Fabrizi F, Cerutti R, Ridruejo E. Hepatitis B virus infection as a risk factor for chronic kidney disease. Expert review of clinical pharmacology. 2019;12(9): 867-874.
40. Chen Y-C, Su Y-C, Li C-Y, Hung S-K. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. BMC nephrology. 2015;16(1): 110.
41. Hong YS, Ryu S, Chang Y, et al. Hepatitis B virus infection and development of chronic kidney disease: a cohort study. BMC nephrology. 2018;19(1): 353.
42. Si J, Yu C, Guo Y, et al. Chronic hepatitis B virus infection and risk of chronic kidney disease: a population-based prospective cohort study of 0.5 million Chinese adults. BMC medicine. 2018;16(1): 93.
43. Kayaaslan B, Guner R. Adverse effects of oral antiviral therapy in chronic hepatitis B. World journal of hepatology. 2017;9(5): 227.
44. Lok AS, McMahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta‐analysis. Hepatology. 2016;63(1): 284-306.
45. Fung J, Lai C-L, Seto W-K, Yuen M-F. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B. Journal of antimicrobial chemotherapy. 2011;66(12): 2715-2725.
46. Mauss S, Berger F, Filmann N, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. Journal of hepatology. 2011;55(6): 1235-1240.
47. Mak L-Y, Seto W-K, Lai C-L, Yuen M-F. DNA polymerase inhibitors for treating hepatitis B: a safety evaluation. Expert Opinion on Drug Safety. 2016;15(3): 383-392.
48. Wong VW-S, Wong GL-H, Chu WC-W, et al. Hepatitis B virus infection and fatty liver in the general population. Journal of hepatology. 2012;56(3): 533-540.
49. Cheng Y-L, Wang Y-J, Kao W-Y, et al. Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PloS one. 2013;8(8).
50. Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology. 2017;65(3): 828-835.
51. Chen C-H, Huang M-H, Yang J-C, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. Journal of clinical gastroenterology. 2006;40(8): 745-752.
52. Lu Z-Y, Shao Z, Li Y-L, Wulasihan M, Chen X-H. Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: an 8-year follow-up study. World Journal of Gastroenterology. 2016;22(13): 3663.
53. Liu H-W, Liu J-S, Kuo K-L. Association of nonalcoholic fatty liver and chronic kidney disease: An analysis of 37,825 cases from health checkup center in Taiwan. Tzu-Chi Medical Journal. 2020;32(1): 65.
54. Akahane T, Akahane M, Namisaki T, et al. Association between Non-Alcoholic Fatty Liver Disease and Chronic Kidney Disease: A Cross-Sectional Study. Journal of Clinical Medicine. 2020;9(6): 1635.
55. Xu H-W, Hsu Y-C, Chang C-H, Wei K-L, Lin C-L. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease. Hepatology international. 2016;10(2): 340-346.
56. Wijarnpreecha K, Thongprayoon C, Scribani M, Ungprasert P, Cheungpasitporn W. Noninvasive fibrosis markers and chronic kidney disease among adults with nonalcoholic fatty liver in USA. European journal of gastroenterology hepatology. 2018;30(4): 404-410.
57. Zhang M, Lin S, Wang M-f, et al. Association between NAFLD and risk of prevalent chronic kidney disease: why there is a difference between east and west? BMC gastroenterology. 2020;20: 1-7.
58. Hui R, Seto WK, Cheung KS, et al. Inverse relationship between hepatic and hepatitis B viremia: Results of a large case‐control study. Journal of viral hepatitis. 2018;25(1): 97-104.
59. Li T-C, Yu T-Y, Li C-I, et al. Three-year renal function trajectory and its association with adverse renal event in patients with type 2 diabetes. Journal of Diabetes and its Complications. 2018;32(8): 784-790.
60. Jiang G, Luk AOY, Tam CHT, et al. Progression of diabetic kidney disease and trajectory of kidney function decline in Chinese patients with type 2 diabetes. Kidney international. 2019;95(1): 178-187.
61. Weldegiorgis M, de Zeeuw D, Li L, et al. Longitudinal estimated GFR trajectories in patients with and without type 2 diabetes and nephropathy. American Journal of Kidney Diseases. 2018;71(1): 91-101.
62. Coresh J, Turin TC, Matsushita K, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. Jama. 2014;311(24): 2518-2531.
63. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. Jama. 2011;305(24): 2532-2539.
64. USRDS. Incidence, prevalence, patient characteristics, and treatment modalities: USRDS Ann Arbor, MI; 2016.
65. Jones CA. Hypertension and renal dysfunction: NHANES III. Journal of the American Society of Nephrology. 2003;14(suppl 2): S71-S75.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/76935-
dc.description.abstract背景
非酒精性脂肪肝是目前全球導致肝功能異常的常見原因,並且它被認為是一種多系統的疾病,不僅會影響肝臟相關器官,甚至會影響肝外器官,包括腎臟。此外,慢性B型肝炎病毒是主要導致肝臟疾病的原因,而某些形態的腎臟功能不全也被認為是與B型肝炎病毒有關的;但慢性B型肝炎病毒與非酒精性脂肪肝之間呈負相關。
目的
本研究以回溯性縱貫性研究探討慢性B型肝炎病毒感染之男性其非酒精性脂肪肝與慢性腎臟病的長期關係;此外,由於腎絲球過濾率在長期追蹤中隨時間之進展趨勢與非酒精性脂肪肝之關聯仍不明確,因此我們進一步比較不同腎絲球過濾率trajectory patterns其非酒精性脂肪肝與其他危險因子之情形。
材料與方法
本研究以過去收集之公務人員門診中心(government employee central clinic, GECC)世代為研究對象,其參與者共有2904名慢性B型肝炎感染之男性。本研究以1989-1992年間進入研究之40歲以上,並在1993-1994年間進行第一次脂肪肝測量,且於1997–2004年間有至少兩次追蹤資料者為研究世代,最終共納入1071名慢性B型肝炎病毒感染之男性進入研究。有無脂肪肝之情形是以腹部超音波檢查之肝臟超音波來診斷;分別以CKD-EPI、台灣CKD-EPI、MDRD以及台灣MDRD四種公式估算腎絲球過濾率(eGFR),作為判定腎臟功能之指標。以eGFR<60 mL/min/1.73 m²定義為CKD;CKD分期則是以KDOQI提出之腎臟病指引共分為6期。以Generalized estimating equation及Generalized linear mixed model對長期追蹤資料進行分析。在追蹤期間,腎絲球過濾率的trajectory patterns是利用latent-class trajectory model進行其趨勢的模擬。並以Kaplan-Meier方法來檢驗CKD惡化的累積發生率。
結果
在基線時,有55.3%的參與者有脂肪肝的情形。分別以CKD-EPI、台灣CKD-EPI、MDRD以及台灣MDRD公式計算eGFR,eGFR<60 mL/min/1.73 m²之比率分別為4.9%、13.2%、8.1%及19.9%。年齡、空腹血糖以及基線時的腎絲球過濾率會與慢性腎臟病的發生有關,然而,非酒精性脂肪肝與慢性腎臟病之間則不存在相關。不論以任一種公式估算之腎絲球過濾率,我們發現了三種不同的軌跡:有30.5%–52.5%的參與者持續有較高的腎絲球過濾率,其腎絲球過濾率為>70 mL/min/1.73 m²;43.9%–65.0%的參與者之腎絲球過濾率較穩定的介於60–70 mL/min/1.73 m²;3.6%–4.5%的參與者則有腎絲球過濾率下降較快的情形,而其在最初的腎絲球過濾率為<60 mL/min/1.73 m²。在腎絲球過濾率下降較快的組別中,年齡最大、肥胖的比率較高,而有糖尿病、高血壓及心血管疾病病史的比率也都最高;然而,三組中非酒精性脂肪肝的情形則沒有顯著差異。此外,以慢性腎臟病期別定義腎臟功能惡化的情形,有糖尿病的參與者發生腎臟功能惡化顯著高於非糖尿病者,其六年累積發生率分別為51.9%及36.0%;然而,有無脂肪肝與腎臟功能惡化間依然沒有發現顯著相關。
結論
本研究之結果發現,對於慢性B肝患者,NAFLD可能不是發生CKD或CKD惡化的獨立危險因子。建議未來可以納入非慢性B肝患者進一步進行探討。
zh_TW
dc.description.abstract
Background
Non-alcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease worldwide. Furthermore, NAFLD is a multisystem disease, which does not only affect liver, but also affects extra-hepatic organs, including kidney. Besides, chronic hepatitis B virus (HBV) infection is a main cause of liver disease and has been associated with various forms of renal impairment. Paradoxically, there is an inverse association between chronic HBV infection and NAFLD.
Specific Aims
We conducted a retrospective longitudinal study of NAFLD and chronic kidney disease (CKD) based on a long-term cohort study of chronic HBV carriers. We aimed to investigate the longitudinal relationship with CKD for the presence of NAFLD. In addition, because the association between progressive nature of eGFR across long-term follow-up and NAFLD remains unclear, we also compared trajectory patterns of eGFR between individuals with and without NAFLD, with the incorporation of other risk factors.
Materials and Methods
Prospective data were from the Government Employees’ Central Clinics cohort study of 2904 male HBV carriers recruited between 1989 and 1992. A total of 1071 participants who were aged above 40, with initial ultrasonography measurement of fatty liver during 1993-1994, underwent at least 2 times of follow-up examinations between 1997-2004 were included. NAFLD was defined as the presence of ultrasonographic fatty liver. CKD was defined as eGFR<60 mL/min/1.73 m², estimated by four equation: CKD-EPI, Taiwan’s CKD-EPI, MDRD, and Taiwan’s MDRD. CKD stages were defined according to KDOQI guidelines. Generalized estimating equation and generalized linear mixed model were used to examine longitudinal data. Trajectories of eGFR over follow-up period were determined using latent-class trajectory modeling. The Kaplan-Meier method was used to investigate the cumulative incidence rate.
Results
At baseline, 55.3% of the participants had NAFLD. The proportion of eGFR<60 mL/min/1.73 m² were 4.9%, 13.2%, 8.1% ,and 19.9%, respectively, according to the formula by CKD-EPI, Taiwan’s CKD-EPI, MDRD, and Taiwan’s MDRD. Age, fasting glucose, and baseline eGFR were associated with the risk of CKD, while no association was detected for NAFLD. We identified three distinct trajectory patterns of eGFR-tracked over time, irrespective of different formulas: 30.5%-52.5% of subjects had persistently high level of eGFR of >70 mL/min/1.73 m², 43.9%-65.0% of subjects had stable levels of eGFR of 60-70 mL/min/1.73 m², and 3.6%-4.5% of subjects had accelerated decline of eGFR from level of eGFR<60 mL/min/1.73m². Subjects with accelerated decline of eGFR trajectory were more likely to be older, more obese, and have a history of diabetes, hypertension, or cardiovascular disease. However, no association was observed for fatty liver. Besides, the 6-year cumulative incidence of renal function deterioration, which was defined as a drop in CKD stages, was significantly higher in diabetes subjects (51.9%) compared to non-diabetes subjects (36.0%). Again, no association with renal function deterioration for NAFLD was observed.
Conclusion
We found that NAFLD might not be an independent risk factor of CKD and progressive CKD in chronic HBV carriers. Further studies are warranted to examine people without HBV.
en
dc.description.provenanceMade available in DSpace on 2021-07-10T21:40:56Z (GMT). No. of bitstreams: 1
U0001-0608202015154900.pdf: 1987713 bytes, checksum: 12cbbec156ec28b463f040991e3bea93 (MD5)
Previous issue date: 2020
en
dc.description.tableofcontents中文摘要...................................i
Abstract..................................iii
目錄.......................................v
表目錄.....................................vi
圖目錄.....................................vii
第一章 研究背景.............................1
第二章 研究目的.............................8
第三章 材料與方法...........................9
資料庫.................................9
研究設計及研究對象......................9
變項定義...............................9
統計方法...............................10
第四章 研究結果.............................11
基線人口學及臨床特性.....................11
eGFR trajectory patterns...............11
NAFLD與CKD間的長期關係..................12
CKD惡化之情形..........................12
第五章 討論................................14
第六章 結論................................18
參考文獻...................................19
dc.language.isozh-TW
dc.subject慢性腎臟病zh_TW
dc.subject腎絲球過濾率(eGFR)zh_TW
dc.subjecttrajectory patternszh_TW
dc.subject非酒精性脂肪肝zh_TW
dc.subject慢性B型肝炎病毒zh_TW
dc.subjecttrajectory patternsen
dc.subjecteGFRen
dc.subjectchronic hepatitis B virusen
dc.subjectchronic kidney diseaseen
dc.subjectnon-alcoholic fatty liver diseaseen
dc.title慢性B型肝炎病毒感染族群非酒精性脂肪肝與慢性腎臟病之長期追蹤研究
zh_TW
dc.titleNon-alcoholic Fatty Liver Disease and Chronic Kidney Disease in Chronic Hepatitis B Virus Carriers: A Longitudinal Studyen
dc.typeThesis
dc.date.schoolyear108-2
dc.description.degree碩士
dc.contributor.oralexamcommittee李文宗(Wen-Chung Lee),程蘊菁(YEN-CHING CHEN),廖勇柏(Yung-Po Liaw),黃奕文(Yi-Wen Huang)
dc.subject.keyword非酒精性脂肪肝,慢性腎臟病,慢性B型肝炎病毒,腎絲球過濾率(eGFR),trajectory patterns,zh_TW
dc.subject.keywordnon-alcoholic fatty liver disease,chronic kidney disease,chronic hepatitis B virus,eGFR,trajectory patterns,en
dc.relation.page42
dc.identifier.doi10.6342/NTU202002547
dc.rights.note未授權
dc.date.accepted2020-08-10
dc.contributor.author-college公共衛生學院zh_TW
dc.contributor.author-dept流行病學與預防醫學研究所zh_TW
顯示於系所單位:流行病學與預防醫學研究所

文件中的檔案:
檔案 大小格式 
U0001-0608202015154900.pdf
  未授權公開取用
1.94 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved